| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 1/08/2025 |
| prilocaine~lidocaine | Gel | 42.5 mg~42.5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 1/08/2025 |
| temozolomide | Capsule, hard | 5 mg | Anticipated | Available | Manufacturing | 1/08/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 1/08/2025 |
| isotretinoin | Capsule, soft | 20 mg | Current | Limited Availability | Manufacturing | 1/08/2025 |
| entacapone~levodopa~carbidopa monohydrate | Tablet, film coated | 200 mg~200 mg~54 mg | Current | Unavailable | Manufacturing | 1/08/2025 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Anticipated | Available | Manufacturing | 1/08/2025 |
| milrinone | Injection, concentrated | 10 mg | Current | Limited Availability | Manufacturing | 1/08/2025 |
| salmeterol xinafoate~fluticasone propionate | Inhalation, powder for | 72.5 microgram/actuation~250 microgram/actuation | Anticipated | Available | Unexpected increase in consumer demand | 1/08/2025 |
| Follitropin alfa | Injection, solution | 150 IU | Resolved | Available | Manufacturing | 1/08/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Limited Availability | Manufacturing | 1/08/2025 |
| nicorandil | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 1/08/2025 |
| tobramycin | Inhalation, conventional | 300 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 1/08/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Resolved | Available | Manufacturing | 1/08/2025 |
| omeprazole | Capsule | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/08/2025 |
| Peginterferon alfa2a | Injection, solution | 135 microgram | Current | Unavailable | Unexpected increase in consumer demand | 1/08/2025 |
| Peginterferon alfa2a | Injection, solution | 180 microgram | Current | Unavailable | Unexpected increase in consumer demand | 1/08/2025 |
| terbinafine hydrochloride | Tablet, uncoated | 281.25 mg | Anticipated | Available | Manufacturing | 31/07/2025 |
| tramadol hydrochloride | Capsule | 50 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| indapamide hemihydrate | Tablet, modified release | 1.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| pioglitazone hydrochloride | Tablet | 16.63 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| exemestane | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 31/07/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| trimethoprim~sulfamethoxazole | Tablet, uncoated | 160 mg~800 mg | Anticipated | Available | Manufacturing | 31/07/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 100 mg~27 mg~200 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 33.75 mg~200 mg~125 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| carbidopa monohydrate~levodopa~entacapone | Tablet, film coated | 40.5 mg~150 mg~200 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| bosentan monohydrate | Tablet, film coated | 129.082 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| entecavir | Tablet, film coated | .5 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| esomeprazole | Capsule, enteric | 20 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 31/07/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Anticipated | Available | Unexpected increase in consumer demand | 31/07/2025 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Resolved | Available | Manufacturing | 31/07/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| mebeverine hydrochloride | Tablet, film coated | 135 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| encorafenib | Capsule, hard | 50 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Resolved | Available | Manufacturing | 31/07/2025 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Resolved | Available | Manufacturing | 31/07/2025 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| levothyroxine sodium | Tablet | 75 microgram | Current | Unavailable | Manufacturing | 31/07/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| risperidone | Tablet, film coated | 1 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| risperidone | Tablet, film coated | 3 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| risperidone | Tablet, film coated | 4 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| risperidone | Tablet, film coated | 2 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| risperidone | Tablet, film coated | .5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/07/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.96 mg | Current | Unavailable | Manufacturing | 31/07/2025 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Manufacturing | 31/07/2025 |
| phenobarbital sodium | Injection, solution | 219 mg/mL | Current | Unavailable | Manufacturing | 30/07/2025 |
| sumatriptan succinate | Tablet, film coated | 139.98 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| bazedoxifene acetate~conjugated estrogens | Tablet, modified release | 22.56 mg~.45 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/07/2025 |
| azacitidine | Injection, powder for | 100 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| cidofovir | Injection, concentrated | 75 mg/mL | Anticipated | Available | Manufacturing | 30/07/2025 |
| neratinib maleate | Tablet, film coated | 48.31 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/07/2025 |
| ceftazidime pentahydrate~avibactam sodium | Injection, powder for | 2329.7 mg~543.5 mg | Resolved | Available | Unexpected increase in consumer demand | 30/07/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 30/07/2025 |
| Trastuzumab | Injection, powder for | 60 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| Trastuzumab | Injection, powder for | 150 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Anticipated | Available | Manufacturing | 30/07/2025 |
| erlotinib hydrochloride | Tablet, film coated | 27.32 mg | Current | Unavailable | Unexpected increase in consumer demand | 30/07/2025 |
| flucloxacillin sodium monohydrate | Injection, powder for | 544.1 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 30/07/2025 |
| pomalidomide | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| bortezomib | Injection, solution | 3.5 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Anticipated | Available | Manufacturing | 30/07/2025 |
| levothyroxine sodium | Tablet | 200 microgram | Current | Unavailable | Unexpected increase in consumer demand | 30/07/2025 |
| glyceryl trinitrate | Drug delivery system, transdermal | 54 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 30/07/2025 |
| labetalol hydrochloride | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 30/07/2025 |
| flecainide acetate | Tablet, uncoated | 100 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| albendazole | Tablet, chewable | 400 mg | Current | Unavailable | Manufacturing | 30/07/2025 |
| ramipril | Tablet, uncoated | 1.25 mg | Anticipated | Available | Manufacturing | 29/07/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Emergency Supply Only | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| bicalutamide | Tablet, film coated | 50 mg | Resolved | Available | Unexpected increase in consumer demand | 29/07/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Current | Limited Availability | Unexpected increase in consumer demand | 29/07/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Limited Availability | Manufacturing | 29/07/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in consumer demand | 29/07/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~10 mg | Current | Limited Availability | Manufacturing | 29/07/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~20 mg | Current | Limited Availability | Manufacturing | 29/07/2025 |
| clopidogrel besilate | Tablet, film coated | 112.1 mg | Current | Unavailable | Manufacturing | 29/07/2025 |
| lacosamide | Tablet, film coated | 200 mg | Resolved | Available | Manufacturing | 29/07/2025 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Resolved | Available | Manufacturing | 29/07/2025 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Anticipated | Available | Unexpected increase in consumer demand | 29/07/2025 |
| methylphenidate hydrochloride | Capsule, hard | 20 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| Teriparatide | Injection, solution | .25 mg/mL | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| framycetin sulfate | Eye and Ear Drops | 5 mg/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 29/07/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2025 |
| phenoxybenzamine hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Manufacturing | 28/07/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Anticipated | Available | Manufacturing | 28/07/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Current | Limited Availability | Manufacturing | 28/07/2025 |
| metronidazole | Tablet, uncoated | 400 mg | Current | Limited Availability | Manufacturing | 28/07/2025 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 12.5 mg~300 mg | Resolved | Available | Manufacturing | 28/07/2025 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 28/07/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Resolved | Available | Manufacturing | 28/07/2025 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 28/07/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Resolved | Available | Manufacturing | 28/07/2025 |
| larotrectinib sulfate | Capsule, hard | 30.7 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/07/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Resolved | Available | Manufacturing | 28/07/2025 |
| dorzolamide hydrochloride~timolol maleate | Eye Drops, solution | 22.26 mg/mL~6.83 mg/mL | Resolved | Available | Manufacturing | 28/07/2025 |
| heparin sodium | Injection, solution | 5000 IU | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 28/07/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 28/07/2025 |
2025年8月4日